Technical analysis of Tivic Health Systems, Inc. (TIVC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | -30.34% |
| 1 year | -67.21% |
| 3 years | -97.37% |
52-Week Range
| 52-week High | $6.95 |
| 52-week Low | $0.72 |
| Avg Volume (90d) | 769K |
Technical Indicators
| SMA 50 | $0.96 |
| SMA 200 | $2.09 |
| 30-day Volatility (annualised) | 149.7% |
| Price vs SMA 50 | +5.6% |
| Price vs SMA 200 | -51.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.51 | |
| 2025-11 | $1.82 | -27.5% |
| 2025-12 | $1.45 | -20.3% |
| 2026-01 | $1.19 | -17.9% |
| 2026-02 | $0.82 | -31.0% |
| 2026-03 | $0.89 | +7.9% |
| 2026-04 | $1.01 | +14.0% |
Price
| Price | $0.26 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.84 |
| Current Ratio | 1.11 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.66 |